Physician profile
Brian Leng
NPI 1710673108
$3,507.70
in general payments reported to CMS, 2019-2025
20 companies · $2,239 in 2025
The $2,239 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $124 · 2024: $1,144 · 2025: $2,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,154 · Education: $344 · Travel and Lodging: $9.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,154.49 |
| Education | $343.88 |
| Travel and Lodging | $9.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $539.07 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Dermavant Sciences, INC. | $518.16 | 2024 | Vtama |
| Abbvie INC. | $490.63 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $318.27 | 2024-2025 | Sotyktu |
| Genzyme Corporation | $268.50 | 2024-2025 | |
| Amgen INC. | $246.33 | 2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $184.70 | 2025 | Zoryve |
| Janssen Biotech, INC. | $181.11 | 2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $172.73 | 2024-2025 | |
| Galderma Laboratories, L.P. | $152.49 | 2025 | Nemluvio, Aklief |
| Sun Pharmaceutical Industries INC. | $121.28 | 2025 | |
| Sanofi-Aventis U.S. LLC | $99.00 | 2024 | |
| Incyte Corporation | $65.29 | 2024-2025 | Opzelura |
| Organon LLC | $28.34 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.18 | 2025 | Spevigo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $21.73 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $20.67 | 2025 | |
| Smith+Nephew, INC. | $19.62 | 2025 | Collagenase Santyl |
| Regeneron Healthcare Solutions, INC. | $17.05 | 2025 | Dupixent |
| Verrica Pharmaceuticals INC. | $15.55 | 2025 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Leng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.